Isolation of psychedelic-responsive neurons underlying anxiolytic behavioral states

Science. 2024 Nov 15;386(6723):802-810. doi: 10.1126/science.adl0666. Epub 2024 Nov 14.

Abstract

Psychedelics hold promise as alternate treatments for neuropsychiatric disorders. However, the neural mechanisms by which they drive adaptive behavioral effects remain unclear. We isolated the specific neurons modulated by a psychedelic to determine their role in driving behavior. Using a light- and calcium-dependent activity integrator, we genetically tagged psychedelic-responsive neurons in the medial prefrontal cortex (mPFC) of mice. Single-nucleus RNA sequencing revealed that the psychedelic drove network-level activation of multiple cell types beyond just those expressing 5-hydroxytryptamine 2A receptors. We labeled psychedelic-responsive mPFC neurons with an excitatory channelrhodopsin to enable their targeted manipulation. We found that reactivation of these cells recapitulated the anxiolytic effects of the psychedelic without driving its hallucinogenic-like effects. These findings reveal essential insight into the cell-type-specific mechanisms underlying psychedelic-induced behavioral states.

MeSH terms

  • Amphetamines* / pharmacology
  • Animals
  • Anti-Anxiety Agents* / pharmacology
  • Anti-Anxiety Agents* / therapeutic use
  • Anxiety / drug therapy
  • Behavior, Animal / drug effects
  • Channelrhodopsins / genetics
  • Channelrhodopsins / metabolism
  • Female
  • Hallucinogens* / pharmacology
  • Male
  • Mice
  • Neurons* / drug effects
  • Neurons* / metabolism
  • Optogenetics
  • Prefrontal Cortex* / drug effects
  • Prefrontal Cortex* / metabolism
  • Prefrontal Cortex* / physiology
  • Receptor, Serotonin, 5-HT2A / genetics
  • Receptor, Serotonin, 5-HT2A / metabolism
  • Serotonin Receptor Agonists* / pharmacology
  • Single-Cell Analysis

Substances

  • Anti-Anxiety Agents
  • Channelrhodopsins
  • Hallucinogens
  • Receptor, Serotonin, 5-HT2A
  • 4-iodo-2,5-dimethoxyphenylisopropylamine
  • Amphetamines
  • Serotonin Receptor Agonists